Skip to main content
. Author manuscript; available in PMC: 2015 Mar 18.
Published in final edited form as: FEBS Lett. 2014 Jan 31;588(6):906–914. doi: 10.1016/j.febslet.2014.01.033

Figure 4. Inhibition of miR-138 prevents chronic activation of cytokine-induced MAPK phosphorylation.

Figure 4

A) Primary HMVECs were treated with Ang II ± antagomir-138 for times indicated and the phosphorylation state of the MAPK p38 and ERK1/2 were assessed by Immunoblot analysis. Representative images are shown. Experiment was repeated twice more, for quantification see Figure S12. B) Primary HMVECs were treated with Ang II ± antagomir-138 ± L-NAME (NOS inhibitor) for times indicated and the phosphorylation state of the MAPK p38 and ERK1/2 were assessed by Immunoblot analysis. Representative image is shown. Experiment was repeated twice more, for quantification see Figure S14.